Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 3/20 | 0.42 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.42 |
| ▸ | SRR | Q9GZT4 | 2/20 | 0.41 |
| ▸ | PSAT1 | Q9Y617 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 8/20 | 0.40 |
| ▸ | PPARA | Q07869 | 7/20 | 0.40 |
| ▸ | PPARD | Q03181 | 1/20 | 0.40 |
| ▸ | MME | P08473 | 5/20 | 0.40 |
| ▸ | ACE | P12821 | 5/20 | 0.40 |
| ▸ | ACE2 | Q9BYF1 | 4/20 | 0.40 |
| ▸ | CPA1 | P15085 | 3/20 | 0.40 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4600067 | 0.93 | CTRB1 (0.40) | ITGA4ITGB1SRRALDH1A1MAPT | |
| SCHEMBL5407004 | 0.93 | CTRB1 (0.40) | ITGA4ITGB1SRRALDH1A1MAPT | |
| SCHEMBL30510366 | 0.93 | CTRB1 (0.40) | ITGA4ITGB1SRRALDH1A1MAPT | |
| SCHEMBL4600752 | 0.93 | CTRB1 (0.40) | ITGA4ITGB1SRRALDH1A1MAPT | |
| SCHEMBL25177964 | 0.91 | ATM (0.39) | ITGA4ITGB1ALDH1A1PPARGPPARA | |
| SCHEMBL30767800 | 0.91 | ATM (0.39) | ITGA4ITGB1ALDH1A1PPARGPPARA | |
| SCHEMBL3834577 | 0.90 | MEN1 (0.38) | ITGA4ITGB1PPARGPPARAMME | |
| SCHEMBL25183089 | 0.90 | C5AR1 (0.43) | ITGA4ITGB1PPARGPPARAITGB7 | |
| SCHEMBL7105951 | 0.90 | NPC1 (0.38) | ITGA4ITGB1PPARGPPARA | |
| SCHEMBL7412293 | 0.90 | MEN1 (0.38) | ITGA4ITGB1PPARGPPARAMME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7202269-B2 | GlyT2 modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-10 | — | — | US | disclosed |
| US-20050119245-A1 | GlyT2 modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-06-02 | — | — | US | disclosed |
| WO-2005044810-A1 | GLYT2 MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119245-A1 | GlyT2 modulators | GLRB, GLRA1, GLRA2 | ITGA4 4322/4885ITGB1 3407/4885SRR 2075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.